03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate of...
20:44 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Alexion submits BLA for long-acting C5 inhibitor for PNH

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) submitted a BLA to FDA for ALXN1210 to treat paroxysmal nocturnal hemoglobinuria (PNH) using a rare disease Priority Review voucher. The submission is based on data from the Phase III ALXN1210-PNH-301 and...
17:58 , May 11, 2018 |  BC Week In Review  |  Company News

EPO rejects Soliris patent, schedules oral hearing

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said the European Patent Office has rejected a patent that would extend exclusivity through 2027 for rare disease drug Soliris eculizumab. An oral hearing has been scheduled for Feb. 5, 2019. The...
20:39 , May 8, 2018 |  BC Extra  |  Company News

EPO rejects Soliris patent, schedules oral hearing

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said the European Patent Office has rejected a patent that would extend exclusivity through 2027 for rare disease drug Soliris eculizumab. An oral hearing has been scheduled for Feb. 5, 2019. The...
19:51 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

Alexion's long-acting C5 inhibitor meets in Phase III switch trial

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported in its 1Q18 earnings release on April 26 that ALXN1210, its long-acting formulation of Soliris eculizumab, met the primary and four key secondary endpoints in the the Phase III ALXN1210-PNH-302...
19:19 , Apr 26, 2018 |  BC Extra  |  Clinical News

Alexion gains on long-acting C5 inhibitor data, guidance

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported in its 1Q18 earnings release on Thursday that ALXN1210, its long-acting formulation of Soliris eculizumab, met the primary and four key secondary endpoints in the the Phase III ALXN1210-PNH-302 trial...
17:39 , Apr 20, 2018 |  BioCentury  |  Finance

Refilling Alexion’s cupboard

The first deal by Alexion Pharmaceuticals Inc.’s freshly rebuilt management team serves to amplify its biggest challenge -- it needs many more external assets to break its Soliris eculizumab dependence, and it may not have...
13:41 , Apr 13, 2018 |  BC Week In Review  |  Company News

Alexion acquires Wilson, adds late-stage asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is acquiring Wilson Therapeutics AB (SSE:WTX) for SEK232 per share in cash, or about SEK7.1 billion ($848 million). The price represents a 70% premium to Wilson's April 10 close of SEK136.20,...
19:15 , Apr 11, 2018 |  BC Extra  |  Company News

Alexion acquires Wilson, adds late-stage asset

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is acquiring Wilson Therapeutics AB (SSE:WTX) for SEK232 per share in cash, or about SEK7.1 billion ($848 million). The price represents a 70% premium to Wilson's Tuesday close of SEK136.20, before...